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1. INTRODUCTION {#tbed12749-sec-0001}
===============

The swine industry is a major part of the global livestock industry and an important part of the food supply chain. The global pig industry produced approximately 963 million pigs and 109 million metric tons of pork in 2011 (<http://www.mbio.ncsu.edu/BioEdit/bioedit.html>). Infectious diseases such as foot‐and‐mouth disease (FMD), classical swine fever (CSF) and African swine fever (ASF) are highly contagious viral diseases reportable to the OIE (World Organization for Animal Health) that can have a severe economic impact on affected areas due to production losses and the impact on the international trade of animals and animal products with disease‐free countries. For example, the 2001 FMD outbreak in the United Kingdom had an estimated cost of \$13 billion US (Thompson et al., [2002](#tbed12749-bib-0044){ref-type="ref"}). The direct costs of the 1997--1998 CSF epizootic in the Netherlands, excluding loss of exports, amounted to \$2 billion US and the slaughter of approximately 10 million pigs (Terpstra & de Smit, [2000](#tbed12749-bib-0043){ref-type="ref"}).

FMD affects over 70 species of cloven‐hoofed animals including cattle, pigs, sheep, goats and wild ruminants causing vesicular lesions on the mouth and hoof (Hedger, Condy, & Gradwell, [1980](#tbed12749-bib-0012){ref-type="ref"}). The disease is endemic in many parts of South America, Asia and Africa. The aetiological agent is the FMD virus (FMDV, *Picornaviridae, Aphthovirus*). Non‐FMD viruses that can cause clinically indistinguishable vesicular lesions in swine include swine vesicular disease virus (SVDV, *Picornaviridae, Enterovirus*) and vesicular exanthema of swine virus (VESV, *Caliciviridae*), a virus derived from feeding pigs seal meat contaminated with San Miguel sea lion virus (SMSV; Zimmerman, Karriker, Ramirez, Schwartz, & Stevenson, [2012](#tbed12749-bib-0047){ref-type="ref"}). CSF virus (CSFV, *Flaviviridae*) causes haemorrhagic disease in pigs (Giammarioli, Pellegrini, Casciari, & Mia, [2008](#tbed12749-bib-0010){ref-type="ref"}) and lesions in less severe cases (Zimmerman et al., [2012](#tbed12749-bib-0047){ref-type="ref"}). African swine fever virus (ASFV, *Asfarviridae*) also causes haemorrhagic fever (Costard et al., [2009](#tbed12749-bib-0005){ref-type="ref"}; Giammarioli et al., [2008](#tbed12749-bib-0010){ref-type="ref"}) that is clinically indistinguishable from infection with CSFV.

For the laboratory diagnosis of vesicular diseases, the OIE currently recommends methods such as virus isolation, antigen capture enzyme‐linked immunosorbent assay (ELISA) and PCR, including real‐time PCR. Virus isolation is often considered the gold standard, but ELISA and real‐time reverse transcriptase (RT)‐PCR are faster and thus more suitable for use as screening tests. Conventional and real‐time RT‐PCR assays have been developed for CSFV (Wernike, Hoffmann, & Beer, [2013](#tbed12749-bib-0045){ref-type="ref"}), ASFV (Fernández‐Pinero et al., [2013](#tbed12749-bib-0009){ref-type="ref"}) and FMDV (Hole, Clavijo, & Pineda, [2006](#tbed12749-bib-0014){ref-type="ref"}; King et al., [2006](#tbed12749-bib-0018){ref-type="ref"}; Reid et al., [2009](#tbed12749-bib-0034){ref-type="ref"}) and its differentials that include vesicular stomatitis virus (VSV; Hole et al., [2006](#tbed12749-bib-0014){ref-type="ref"}; Rasmussen, Uttenthal, & Agüero, [2006](#tbed12749-bib-0033){ref-type="ref"}), SVDV (Fernández et al., [2008](#tbed12749-bib-0008){ref-type="ref"}; Núñez et al., [1998](#tbed12749-bib-0031){ref-type="ref"}), and VESV (Reid et al., [2007](#tbed12749-bib-0035){ref-type="ref"}). User‐friendly reverse transcription insulated isothermal PCR (RT‐iiPCR) assays performed on compact, field‐deployable instruments with automatic display of "+" or "−" results have also been described for CSFV (Lung et al., [2015](#tbed12749-bib-0026){ref-type="ref"}) and FMDV (Ambagala et al., [2016](#tbed12749-bib-0001){ref-type="ref"}). Real‐time multiplex PCR assays have been reported for the detection of FMDV and CSFV (Shi et al., [2016](#tbed12749-bib-0041){ref-type="ref"}; Wernike et al., [2013](#tbed12749-bib-0045){ref-type="ref"}) and other targets (Haines, Hofmann, King, Drew, & Crooke, [2013](#tbed12749-bib-0011){ref-type="ref"}; Li et al., [2013](#tbed12749-bib-0021){ref-type="ref"}; Rasmussen et al., [2006](#tbed12749-bib-0033){ref-type="ref"}; Wernike et al., [2012](#tbed12749-bib-0046){ref-type="ref"}). Although RT‐iiPCR and real‐time RT‐PCR are rapid and highly sensitive, separate single‐target reactions are normally performed by the Canadian Food Inspection Agency\'s National Centre for Foreign Animal Disease when testing for the presence of foreign animal disease pathogens. Thus, a user‐friendly, multiplex diagnostic test for differential diagnosis of high‐consequence foreign animal diseases could be a useful tool.

In addition to the major vesicular diseases of swine, CSFV and ASFV, two viruses indigenous to North America; porcine circovirus type 2 (PCV2, *Circoviridae*) and porcine respiratory and reproductive syndrome virus (PRRSV, *Arteriviridae*), which are responsible for most of the production losses to the North American pig industry (Nicholson et al., [2011](#tbed12749-bib-0030){ref-type="ref"}; Zimmerman et al., [2012](#tbed12749-bib-0047){ref-type="ref"}), were also tested with available resources to evaluate the potential of this technology for testing of indigenous diseases. Depending on the strain of the virus and the immune status of the host, there is considerable variation in clinical signs of PRRS. Typically, PRRSV infection causes mild to severe respiratory disease in newborn and growing pigs and reproductive failure in pregnant sows (Lunney et al., [2016](#tbed12749-bib-0027){ref-type="ref"}) and can also cause apoptosis in organs such as the lungs, testes, lymph nodes and thymus (Karniychuk et al., [2011](#tbed12749-bib-0017){ref-type="ref"}). PCV2 infection can lead to lymphoid depletion and immunosuppression in pigs and is the primary causative agent of porcine circovirus‐associated disease (PCVAD). Infections can also cause wasting and increased mortality, as well as lesions in the lymphatic area (Meng, [2013](#tbed12749-bib-0028){ref-type="ref"}).

Microarrays can accommodate multiple probes for each target that can provide redundancy and broader coverage of viral variants when compared with single probe assays. The development and evaluation of traditional microarrays for subtyping and multiplex detection of viruses that affect livestock have been previously described (Banér et al., [2007](#tbed12749-bib-0002){ref-type="ref"}; Hindson et al., [2008](#tbed12749-bib-0013){ref-type="ref"}; Jack et al., [2009](#tbed12749-bib-0016){ref-type="ref"}; Lenhoff et al., [2008](#tbed12749-bib-0020){ref-type="ref"}; Lung et al., [2011](#tbed12749-bib-0023){ref-type="ref"}, [2016](#tbed12749-bib-0024){ref-type="ref"}). The assay described by Banér et al. ([2007](#tbed12749-bib-0002){ref-type="ref"}) detected FMDV, SVDV, VSV, and differentiated between the two serotypes of VSV. Lung et al. ([2011](#tbed12749-bib-0023){ref-type="ref"}) described an assay that detected four vesicular disease viruses (FMDV, VSV, SVDV and VESV) and differentiated between the seven serotypes of FMDV (A, O, C, Asia 1, SAT1, SAT2 and SAT3) and the two serotypes of VSV (New Jersey & Indiana). These methods are laborious to perform, utilize conventional slide microarrays that rely on slower passive hybridization and require multiple pieces of equipment for capture probe printing, hybridization, washing, and slide scanning. In this study, the development and initial validation of an electronic microarray platform that integrates and automates capture probe printing with microarray hybridization, washing, and reporting on a single instrument and allows for onsite updating of probe sequences and custom printing of capture probes by the user for the detection of multiple viruses is described.

2. MATERIALS AND METHODS {#tbed12749-sec-0002}
========================

2.1. Viruses {#tbed12749-sec-0003}
------------

Sixty‐eight laboratory and field isolates of the seven targeted swine viruses were used in this study (Tables [1](#tbed12749-tbl-0001){ref-type="table"}, [5](#tbed12749-tbl-0005){ref-type="table"}). The strains tested represent viruses from all seven FMDV serotypes, three CSFV genotypes, and both North American (NA) and European (EU) genotypes of PRRSV that were available for testing at the Canadian Food Inspection Agency (CFIA). Strains of FMDV, SVDV, VESV, CSFV and ASFV were propagated and titered according to previously published methods (Moniwa, Clavijo, Li, Collignon, & Kitching, [2007](#tbed12749-bib-0029){ref-type="ref"}; Senthilkumaran et al., [2016](#tbed12749-bib-0040){ref-type="ref"}). PRRSV RNA and PCV2 DNA were kindly provided by Dr. Markus Czub (University of Calgary, Calgary, Alberta, Canada). PRRSV‐positive field serum samples were kindly provided by Dr. Davor Ojkic (University of Guelph). A panel of 11 samples from animals negative for the target viruses along with 11 non‐target bacteria and viruses that affect livestock were used to evaluate the specificity of the assay: swine influenza virus (SIV), porcine respiratory coronavirus (PRCV) KIVA, transmissible gastroenteritis virus (TGEV) TC1998, porcine circovirus 1 (PCV1), vesicular stomatitis virus (VSV) 89 GAS, bovine viral diarrhoea virus (BVDV) type 1 Singer, Border disease virus (BDV) CoosBay, *Streptococcus suis*,*Pasteurella multocida*,*Salmonella enterica* choleraesuis, and *Mycoplasma hyopneumoniae*.

###### 

Laboratory samples representing the seven targeted swine viruses used in this study

  Virus                     Genotype/Serotype                             Strain name         Country of origin
  ------------------------- --------------------------------------------- ------------------- -------------------
  FMDV                      A                                             Iran 1/96 (FMD 1)   Iran
  ARG 2/2001 (FMD 2)        Argentina                                                         
  ARG/87 (FMD 3)            Argentina                                                         
  COL/85 (FMD 4)            Columbia                                                          
  Iran/99 (FMD 5)           Iran                                                              
  Iraq 24/64 (FMD 6)        Iraq                                                              
  Cruzeiro/Bra/55 (FMD 7)   Brazil                                                            
  O                         Manisa (FMD 8)                                Turkey              
  TAW 10/97 (FMD 9)         Taiwan                                                            
  UKG 11/2001 (FMD 10)      UK                                                                
  BFS/1860 (FMD 11)         UK                                                                
  C                         Noville (FMD 12)                              Switzerland         
  Resende (FMD 13)          Brazil                                                            
  Asia                      PAK 1/54 (FMD 14)                             Pakistan            
  Shamir (FMD 15)           Israel                                                            
  SAT1                      KEN 4/98 (FMD 16)                             Kenya               
  BOT 1/68 (FMD 17)         Botswana                                                          
  SAT2                      ZIM 5/81 (FMD 18)                             Zimbabwe            
  SWA 1/69 (FMD 19)         Swaziland                                                         
  SAU 1/2000 (FMD 20)       Saudi Arabia                                                      
  ZIM 10/91 (FMD 21)        Zimbabwe                                                          
  SAT3                      BEC 1/65 (FMD 22)                             Botswana            
  ZIM 4/81 (FMD 23)         Zimbabwe                                                          
  SVDV                                                                    GRE 1/79            Greece
                            FRA 1/73                                      France              
                            HKN 1/80                                      Hong Kong           
                            HKN 3/89                                      Hong Kong           
                            ITL 1/66                                      Italy               
                            ITL 1/97                                      Italy               
                            JAP 1/74                                      Japan               
                            NET 3/92                                      Netherlands         
                            PORT 1/2003                                   Portugal            
                            SWI 1/74                                      Switzerland         
                            UK 27/72                                      UK                  
                            ITL 19/92                                     Italy               
  CSFV                      1.1                                           Alfort/187          France
  1.2                       Brescia                                       Italy               
  1.3                       VRI 4167                                      Malaysia            
  2.1                       NL B64                                        Spain               
  2.2                       Vi 3295/4/89                                  Germany             
  2.3                       Diepholz 1/Han94                              Germany             
  3.1                       Congenital Tremor                             UK                  
  3.2                       3.2[a](#tbed12749-note-0001){ref-type="fn"}   USA                 
  3.3                       3.3[a](#tbed12749-note-0001){ref-type="fn"}   USA                 
  3.4                       Kanagawa (Tap 3)                              Japan               
  ASFV                      1                                             Lisbon‐61           Portugal
  1                         Lillie                                        France              
  2                         Georgia 2007                                  Georgia             
  VESV                                                                    VESV‐CAL            USA
  PCV2                      Type 2                                        PCV2 B              Canada
  PRRSV                     1                                             PRRS LV             Netherlands
  2                         PRRSV 2.5                                     USA                 
  2                         PRRS Vaccine 2.5                              USA                 
  2                         PRRS 1.4                                      USA                 
  2                         PRRS MLV June 2004                            USA                 
  2                         PRRSV Vac 2,5                                 USA                 
  2                         PRRSV P‐YNL                                   USA                 
  2                         PRRSV 93 44927                                USA                 

Synthetic DNA construct.
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2.2. Samples {#tbed12749-sec-0004}
------------

The details of the inoculation studies in animals and clinical samples were as previously described (Lung et al., [2011](#tbed12749-bib-0023){ref-type="ref"}) or will be described elsewhere for other viruses. All animal studies complied with the guidelines of the Canadian Council on Animal Care.

Clinical samples containing VESV and PCV2 were not available, and thus, oral and nasal material obtained from healthy animals (Prairie Swine Centre, Saskatoon, Saskachewan, Canada) was spiked with cell culture‐amplified viruses for these two viruses and PRRSV.

2.3. Primers and probes {#tbed12749-sec-0005}
-----------------------

PCR primer and capture probe sequences were either identified from the literature, then used with or without modifications or were newly designed (Tables [2](#tbed12749-tbl-0002){ref-type="table"} and [3](#tbed12749-tbl-0003){ref-type="table"}). Primer and probe design were performed as described previously (Lung et al., [2011](#tbed12749-bib-0023){ref-type="ref"}, [2012](#tbed12749-bib-0022){ref-type="ref"}) using AlleleID^®^ v. 7.7 (Premier BioSoft International, Palo Alto, CA, USA), Clone Manager v 9.0 software (Scientific and Educational Software, Cary, NC, USA) and BioEdit (<http://www.mbio.ncsu.edu/BioEdit/bioedit.html>) using all publicly available sequences from NCBI. Primers were tested in silico using IDT\'s OligoAnalyzer 3.1 (<http://www.idtdna.com/calc/analyzer>), and any primers with self‐ and hetero‐dimers with a ΔG ≥ −11 kcal/mole were modified or screened out. The reverse primers were synthesized with the reverse complementary sequence of the NGEN™ Red Universal Reporter Probe (Nexogen, San Diego, CA) at the 5′ end (Lung et al., [2011](#tbed12749-bib-0023){ref-type="ref"}). The primers were also evaluated in silico as previously described (Lung et al., [2017](#tbed12749-bib-0025){ref-type="ref"}) against non‐target viruses using NCBI\'s electronic PCR (e‐PCR, Rotmistrovsky, Jang, & Schuler, [2004](#tbed12749-bib-0036){ref-type="ref"}; Schuler, [1997](#tbed12749-bib-0039){ref-type="ref"}) to evaluate potential cross‐reactivities. Furthermore, all unique primer pairs used in the multiplex PCR were tested against all non‐redundant nucleotide sequences of non‐FMDV picornaviruses (*n* = 61,995 unique sequences). This was achieved using a Python script developed in‐house to generate a multi‐FASTA file with all the unique primer pairs in the multiplex PCR (e.g., the forward primer of FMDV and the reverse primer of ASFV) that target viruses other than the viruses for which the primers were originally designed. The table was used as the input for the e‐PCR program to test the primers in silico. Hits that were returned with less than four mismatches were evaluated with ThermoBLAST\'s in silico simulations under reaction conditions to predict possible hybridizations based on thermodynamic parameters as well as sequence complementarity (SantaLucia, [2007](#tbed12749-bib-0038){ref-type="ref"}). Candidate probes were screened for predicted specificity using NCBI BLAST (<http://blast.ncbi.nlm.nih.gov/Blast.cgi>). Virus‐specific candidate probes that did not show significant matches to the other target viruses (probes exhibiting \<25% overall identity and cross‐homologous regions of less than eight nucleotides) were then screened on the NanoChip400 microarray (Nexogen) against a reference panel of viruses. All capture probes were modified with 5′‐biotinylation to allow attachment to the streptavidin‐containing hydrogel of the microarray. All primers and probes were synthesized by IDT (Integrated DNA Technologies, Coralville, IA, USA).

###### 

PCR primers used in this study

  Virus                                                             Genomic region                                Primer                                                       Sequence (5′‐3′)                            Amplicon size (bp)   Reference
  ----------------------------------------------------------------- --------------------------------------------- ------------------------------------------------------------ ------------------------------------------- -------------------- ------------------------------------------------------------
  FMDV                                                              VP3/VP1/ 2A/2B                                VP3com980(1)                                                 GCT GAT TAC GCG TAC AC                      971                  This study
  VP3com980(2)                                                      GCT GAC TAC GCG TAC AC                        This study                                                                                                                    
  VP3com980(3)                                                      GCG GAT TAC GCC TAC AC                        This study                                                                                                                    
  VP3com980(4)                                                      GCG GAT TAC GCG TAC AC                        This study                                                                                                                    
  VP3com980(5)                                                      GCA GAT TAC GCG TAT AC                        This study                                                                                                                    
  VP3com980(6)                                                      GCA GAC TTT GCA TAC AC                        This study                                                                                                                    
  VP3com980(7)                                                      AGT GAC TTC TCC TAC AC                        This study                                                                                                                    
  VP3com980(8)                                                      GCT GAC TAT GCT TAC AC                        This study                                                                                                                    
  VP3com980(9)                                                      GCA GAC TTT GCC TAY AC                        This study                                                                                                                    
  FMDV 2B Rev 4026‐S‐Deg2[a](#tbed12749-note-0002){ref-type="fn"}   GCG GAC ACC ARC CGG TTR AAG TC                This study                                                                                                                    
  SVDV                                                              3C/3D                                         SVDVCV‐3C‐17a‐F‐(5875bp)                                     CAG CGG CAC TCC TCA GAC ACT AC              791                  Lung et al. ([2011](#tbed12749-bib-0023){ref-type="ref"})
  SVDVCV‐3D‐3a‐R‐(6642bp)[a](#tbed12749-note-0002){ref-type="fn"}   GAG TTT CAG GCA CGT AAA CCA CAC               Lung et al. ([2011](#tbed12749-bib-0023){ref-type="ref"})                                                                     
  CSFV                                                              E1/E2                                         KBH12‐5 E1 Ext FWD                                           AGR CCA GAC TGG TGG CCN TAY GA              671                  Paton et al. ([2000](#tbed12749-bib-0032){ref-type="ref"})
  KBH12‐6 E2 Ext REV[a](#tbed12749-note-0002){ref-type="fn"}        TTY ACC ACT TCT GTT CTC A                     Paton et al. ([2000](#tbed12749-bib-0032){ref-type="ref"})                                                                    
  ASFV                                                              VP72                                          King Long ‐ Fwd Primer                                       ATA GGA TTA AAA CCT ACC TGG AAC ATC TCC G   537                  King et al. ([2003](#tbed12749-bib-0019){ref-type="ref"})
  King Long ‐ Rev Primer[a](#tbed12749-note-0002){ref-type="fn"}    GGT ACT GTA ACG CAG CAC AGC TGA ACC GTT CTG   King et al. ([2003](#tbed12749-bib-0019){ref-type="ref"})                                                                     
  VESV                                                              Polymerase                                    VESVSM‐2‐F‐(5101bp)                                          CGA CTC GAT GGA CCT GTT CAC ATA CG          649                  Lung et al. ([2011](#tbed12749-bib-0023){ref-type="ref"})
  VESVSM‐5‐R‐(5749bp)[a](#tbed12749-note-0002){ref-type="fn"}       CGT AGA GGT CGG TTA GGT CCT TTC TG            Lung et al. ([2011](#tbed12749-bib-0023){ref-type="ref"})                                                                     
  PCV2                                                              Capsid                                        CircoV‐1222F                                                 GTA ATC AAT AGT GGA ATC TAG GAC             534                  Lung et al. ([2017](#tbed12749-bib-0025){ref-type="ref"})
  CircoV ‐1760R[a](#tbed12749-note-0002){ref-type="fn"}             TTC GTT TTC AGA TAT GAC GTA TC                Lung et al. ([2017](#tbed12749-bib-0025){ref-type="ref"})                                                                     
  PRRSV                                                             Matrix                                        PRRS‐Mtrx‐ F2                                                AAG GTA AGT CGC GGC CGA C                   379                  Lung et al. ([2017](#tbed12749-bib-0025){ref-type="ref"})
  PRRS‐Mtrx ‐R2[a](#tbed12749-note-0002){ref-type="fn"}             TGC CRC CCA ACA CGA GGC                       Lung et al. ([2017](#tbed12749-bib-0025){ref-type="ref"})                                                                     

Reverse primers contain a complimentary tag sequence for Red Universal Reporter probe at the 5′ end (Lung et al., [2012](#tbed12749-bib-0022){ref-type="ref"}).
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###### 

Capture probes used in this study

  Virus/Genomic region    Probe name                                                    Sequence (5′ biotinylation[a](#tbed12749-note-0003){ref-type="fn"} ‐ 3′)   Reference
  ----------------------- ------------------------------------------------------------- -------------------------------------------------------------------------- --------------------------------------------------------------
  FMDV ‐ VP3/VP1/2A/2B    FMD Common A                                                  AAG TTG GCN GGA GAC GTB GAG TCC AAC CC                                     This study
  FMD Common B            AAC TTY GAC CTG TTA AAG TTG GCB GGA GAC GTT GAG TC            This study                                                                 
  FMD Common C            AAC TTC GAC CTG TTA AAG TTG GCY GGA GAC GTT GAG TCC AAC CCT   This study                                                                 
  FMD Common D            GAG TCC AAC CCT GGG CCY TTC TTC TTC                           This study                                                                 
  FMD Common E            GAG AYG TBG AGT CCA ACC CTG GGC CYT T                         This study                                                                 
  SVDV ‐ 3C‐3D            SVDV‐020‐deg                                                  AAG AGA CAT YCT ATC CAA GAA GAC CAG AGA CCT TRC CA                         Lung et al. ([2011](#tbed12749-bib-0023){ref-type="ref"})
  SVDV‐014a               GGG TAG CGC CGT TGG GTG TGA CC                                Lung et al. ([2011](#tbed12749-bib-0023){ref-type="ref"})                  
  SVDV‐008‐deg            GTG GCY YTG GGT ATC AAG AAA AGA GAC AT                        Lung et al. ([2011](#tbed12749-bib-0023){ref-type="ref"})                  
  SVDV‐013                GCA ATG AGG CAG ACA TTT GGA AAC CTA TA                        Lung et al. ([2011](#tbed12749-bib-0023){ref-type="ref"})                  
  SVDV‐016                AAA GAG ACA TCC TAT CCA AGA AGA CCA GAG ACC T                 Lung et al. ([2011](#tbed12749-bib-0023){ref-type="ref"})                  
  SVDV‐010‐deg            TAT GGT CTA AAC YTR CCA ATG GTA ACC TA                        Lung et al. ([2011](#tbed12749-bib-0023){ref-type="ref"})                  
  SVDV‐019‐deg            ACA ACT AGC CAC ACT RGA CAT YAG CAC KGA RC                    Lung et al. ([2011](#tbed12749-bib-0023){ref-type="ref"})                  
  CSFV ‐E1/E2             CSFV Common 1                                                 CTT AAK GTG GTY AGT AGG AGG TAY                                            This study
  CSFV Common 4a          CTG RAY GAC GGR ACY GTY AR                                    This study                                                                 
  bioKBH12‐8 E2 Int FWD   TCR WCA ACC AAY GAG ATA GGG                                   Paton et al. ([2000](#tbed12749-bib-0032){ref-type="ref"})                 
  bioKBH12‐9 E2 Int REV   GAT GAC TTY GGR TTY GGR CTG TG                                Paton et al. ([2000](#tbed12749-bib-0032){ref-type="ref"})                 
  ASFV ‐ VP72             bioASFV‐VP72‐1668                                             CTG CTC ATG GTA TCA ATC TTA TCG A                                          King et al. ([2003](#tbed12749-bib-0019){ref-type="ref"})
  bioASFV‐VP72‐1898       ACG GCY GAT CTT GTG GTA TC                                    King et al. ([2003](#tbed12749-bib-0019){ref-type="ref"})                  
  VESV ‐ Polymerase       VESV‐SM‐010‐deg                                               CCA CYA TGG CTA CTA CTC AYA CGC TTC TGT CGT TTG AC                         Lung et al. ([2011](#tbed12749-bib-0023){ref-type="ref"})
  VESV‐SM‐003a‐deg        CGG ATG CTG ARA TAA CGC CTA TCC C                             Lung et al. ([2011](#tbed12749-bib-0023){ref-type="ref"})                  
  PCV2 ‐ Capsid           CircoV‐1576                                                   ATA TCC GAA GGT GCG GGA T                                                  Lung et al. ([2017](#tbed12749-bib-0025){ref-type="ref"})
  CircoV‐1657             GAC GAG CCA GGG GCG GCG GC                                    Lung et al. ([2017](#tbed12749-bib-0025){ref-type="ref"})                  
  PRRSV ‐ Matrix          PRRS 322‐346 COM                                              TAC ATT CTG GCC CCT GCC CAT CAC G                                          Lung et al. ([2017](#tbed12749-bib-0025){ref-type="ref"})
  PRRSV‐M‐378             GGC AAA TGA TAA CCA CGC ATT TG                                Lung et al. ([2017](#tbed12749-bib-0025){ref-type="ref"})                  
  PRRSV‐M‐361             GGC TTT CAT CCG ATT GCG GCA AAT G                             Lung et al. ([2017](#tbed12749-bib-0025){ref-type="ref"})                  
  PRRS 233‐252 EU         TTG TCA CCC TTC TGT GGG GC                                    Lung et al. ([2017](#tbed12749-bib-0025){ref-type="ref"})                  
  PRRS 380‐402 EU         CGT CTG GTA ACC GAG CAT ACG CT                                Lung et al. ([2017](#tbed12749-bib-0025){ref-type="ref"})                  
  Non‐Specific Binding    NSBP                                                          CAA AGT GGG AGA CGT CGT TG                                                 Hindson et al. ([2008](#tbed12749-bib-0013){ref-type="ref"})

Probes modified with 5′ biotinylation for binding to streptavidin pad on NanoChip 400 microarray (Takahashi, Norman, Mather, & Patterson, [2008](#tbed12749-bib-0042){ref-type="ref"}).
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2.4. Nucleic acid extraction {#tbed12749-sec-0006}
----------------------------

Nucleic acid was extracted from vesicular viruses (FMDV, SVDV and VESV) and clinical samples as described previously (Lung et al., [2011](#tbed12749-bib-0023){ref-type="ref"}), while all other viruses were extracted using the QIAamp Viral RNA Kit (Deregt et al., [2006](#tbed12749-bib-0006){ref-type="ref"}) or the Ambion Mag Max Kit (Thermofisher Scientific‐ Ambion, Burlington, ON, Canada) according to manufacturer\'s specification. Nucleic acid was eluted in 50 μl QIAamp or 90 μl MagMax elution buffer. For PCV2 and PRRSV, 14 μl of the neat laboratory‐propagated virus was spiked into 126 μl of biological material and extracted with the QIAmp viral RNA Kit (Qiagen, Toronto, ON, Canada). For VESV, 20 μl of virus culture was spiked into 120 μl of clinical material and extracted with the QIAamp viral RNA kit. All extracted spiked samples were tested for the presence of target viruses with the seven‐plex assay.

2.5. Multiplex reverse transcription PCR {#tbed12749-sec-0007}
----------------------------------------

A multiplex RT‐PCR consisting of 22 primers was developed to amplify genomic targets of seven swine viruses (FMDV, SVDV, VESV, CSFV, ASFV, PRRSV and PCV2) in a single reaction. The RT‐PCR was performed using the SuperScript^®^ III (SSIII) One‐Step RT‐PCR with Platinum Taq kit (Life Technologies, Burlington, ON, Canada) in a 50‐μl reaction. The RT‐PCR consisted of FMDV, CSFV and PCV2 primers at 1 μM final concentration each, SVDV, VESV, ASFV and PRRSV primers at 0.5 μM final concentration each, 25 μl of 2 ×  RT buffer mix, 2 μl of SSIII enzyme mix, 15 μl of ultrapure water and 1 μl of sample. The RT‐PCRs were run on a Veriti thermal cycler (Life Technologies‐Applied Biosystems, Burlington, ON, Canada) in Lethbridge during initial assay development and switched to 9700 thermal cycler (Life Technologies) at the National Centre for Foreign Animal Disease. The cycling parameters were as follows: 55°C for 15 min for reverse transcription (RT), followed by 94°C for 2 min and then 35 cycles of: 94°C for 30 s, 50°C for 1 min and 68°C for 1 min. This was followed by a final 5‐min extension at 68°C. Post‐amplification reactions were visualized using either the QIAxcel (QIAGEN) instrument or agarose gel electrophoresis with SYBR^®^ safe DNA gel stain (Life Technologies).

2.6. Electronic microarray {#tbed12749-sec-0008}
--------------------------

All buffers used in the computer‐controlled automated electronic microarray assay were from Nexogen, Inc. or prepared in‐house from chemicals purchased from Sigma‐Aldrich (Oakville, ON, Canada). Biotinylated capture probes (250 nM) were prepared in 50 mM L‐histidine/0.05% Proclin^®^ 300 buffer (His/Proclin^®^ buffer, Nexogen Inc.) and electronically addressed to selected electrodes on the NanoChip400 cartridge through the application of a positive 350 nA current for 30 s. After five washes of the cartridge with a mixture of His/Proclin^®^ buffer containing 20% Triton X‐100, and water with 0.05% Proclin^®^ solution, 8.75 μl of unpurified PCR amplicons, diluted 1 of 8 in 61.25 μl Cap‐Down A Buffer were electronically addressed at 800 nA for 60 s to selected electrode pads containing bound capture probes. The cartridge was washed five more times with His/Proclin^®^ buffer, incubated at 40°C for 60 s and washed once with high salt buffer (HSB, Nexogen Inc.). Hybridized amplicons were detected using a fluoresceinated reporter probe resuspended in HSB at 1 μM final concentration and a touchdown passive reporting protocol as described previously (Lung et al., [2012](#tbed12749-bib-0022){ref-type="ref"}). All electronic microarray hybridizations were performed in duplicate, and a non‐template PCR control (NTC) was included in all experiments. Raw fluorescent intensity (FI) data from all utilized pads on each cartridge were obtained and analysed using Microsoft Excel. Positive‐to‐negative (P/N) ratios were calculated by dividing the averaged FI value for each amplicon by the FI value produced by the average NTC for each probe. Samples that produced P/N ratios greater than an empirically determined cut‐off of 2 for both replicates of one or more virus‐specific capture probe were considered positive. P/N data derived from multiple microarrays were visualized through a heat map generated using TreeView (Eisen, Spellman, Brown, & Botstein, [1998](#tbed12749-bib-0007){ref-type="ref"}).

2.7. Analytical sensitivity {#tbed12749-sec-0009}
---------------------------

RNA transcribed from a plasmid (CSFV, PRRSV, SVDV, VESV) or PCR amplicon template (FMDV) was used to determine the limit of detection of the RT‐PCR and the electronic microarray for the RNA viruses. In vitro transcribed RNA was generated from plasmid templates containing the targeted genomic regions of the swine viruses, blunt ligated into either the pJET1.2 vector (ThermoScientific‐Fermentas, Ottawa, ON) or the pCR™II‐blunt‐TOPO^®^ vector (Life Technologies ‐ Invitrogen, Burlington, ON, Canada). Quantified plasmids were restriction digested with HindIII (10 μ/μl) or other appropriate restriction enzymes when HindIII sites were found within the amplicon (Thermo Scientific‐Fermentas, Ottawa, ON), purified using the Zymo DNA Clean & Concentrator™‐25 column kit (Zymo Research, Irvine, CA) and transcribed using the MEGAscript^®^ kit (Life Technologies). For FMDV, the desired gene regions were synthesized by IDT, cloned into the pGEM‐3Zf(+) vector, digested with EcoRI (Life Technologies, Thermo Scientific‐Fermentas, Ottawa, ON), amplified under the same cycling conditions by the described RT‐PCR in single‐plex and transcribed as described previously (Lung et al., [2015](#tbed12749-bib-0026){ref-type="ref"}). RNA was quantified using the Qubit^®^ 2.0 Fluorometer and RNA broad range assay kit (Life Technologies). For the DNA viruses ASFV and PCV2, plasmids containing the targeted genes were extracted from overnight cultures of *Escherichia coli* transformed with the appropriate plasmid (Sambrook & Russell, [2001](#tbed12749-bib-0037){ref-type="ref"}). Copy number was calculated using the following equation: $$\frac{\text{concentration}\,{(\text{ng})} \times 6.022\, \times \, 10^{23}/\text{mole}}{\text{base}\,\text{pair}\,{(\text{bp})}\, \times \, 1\, \times \, 10^{9}\,{\text{ng}/g}\, \times \,\text{Molecular}\,\text{Weight}\,\text{bp}\,{g/\text{mole}}}$$

After quantification, in vitro transcribed RNA and plasmid DNA were diluted serially 10‐fold from neat stock to 10^−12^ in ultrapure dH~2~O. The dilution series were amplified using the standard seven‐plex multiplex, a five‐plex exotic virus multiplex (all viruses except PRRSV and PCV2), two‐plex indigenous virus multiplex (PRRSV and PCV2) and single‐plex RT‐PCRs and imaged using the QIAxcel Advanced instrument (QIAGEN). RT‐PCR endpoints were determined by the last reaction in the dilution series to give a visually detectable band. In duplicate, a panel of six samples from each dilution series, two samples above the RT‐PCR endpoint, one sample at the endpoint and three samples below the endpoint, were selected and ran on the electronic microarray with a positive control and NTC (*n* = 8). The eight samples were run against the specific target probes (i.e., FMDV samples run on five FMDV probes) as well as the non‐specific binding probe (NSBP) as a negative control. A P/N ratio cut‐off of 2 for positivity was used to determine the analytical sensitivity on the electronic microarray. P/N ratios ≥1.7 and ≤2 were designated as suspect reactors.

3. RESULTS {#tbed12749-sec-0010}
==========

3.1. RT‐PCR amplification {#tbed12749-sec-0011}
-------------------------

The multiplex RT‐PCR utilized 22 primers to amplify selected genomic regions of the seven target viruses (Table [2](#tbed12749-tbl-0002){ref-type="table"}). The RT‐PCR generated amplicons of the expected size for all 68 isolates of the seven target viruses (23 FMDV, 12 SVDV, 10 CSFV, one VESV, three ASFV, one PCV2 and 18 PRRSV; Figures [1](#tbed12749-fig-0001){ref-type="fig"}a and [3](#tbed12749-fig-0003){ref-type="fig"}a). The specificity of the amplification was evaluated using a total of 22 samples, including 11 oral clinical materials from healthy pigs, and 11 non‐target swine bacteria and viruses associated with livestock. Nucleic acid extracted from non‐target pathogens and clinical material from healthy animals either did not generate detectable RT‐PCR products or generated weak, non‐specific products in the absence of templates from target viruses (Figure [1](#tbed12749-fig-0001){ref-type="fig"}b). The non‐specific amplifications were reduced substantially when the same samples were spiked with PRRSV RNA as an exogenous control (Figure [1](#tbed12749-fig-0001){ref-type="fig"}c).

![Amplification of target and non‐targets using the seven‐plex RT‐PCR. (a) QIAxcel gel image of representative amplified products after RT‐PCR amplification of representative strains of the seven targeted swine viruses and oral swab from healthy pigs. Asterisk denotes in vitro transcribed RNA was used as a template. (b) QIAxcel gel image of amplified products from amplification of 11 non‐target virus and bacteria that affect livestock: swine influenza virus (SIV), porcine respiratory coronavirus (PRCV) KIVA, transmissible gastroenteritis virus (TGEV) TC1998, porcine circovirus 1 (PCV1), vesicular stomatitis virus (VSV) 89 GAS,*Streptococcus suis*,*Pasteurella multocida*,*Salmonella enterica* choleraesuis*, Mycoplasma hyopneumoniae*, bovine viral diarrhoea virus (BVDV) type 1 Singer, and Border disease virus (BDV) CoosBay. (c) Amplification of nucleic acid from non‐target bacteria and viruses spiked with PRRSV YNL RNA as an exogenous control. NTC: no template control](TBED-65-e272-g001){#tbed12749-fig-0001}

3.2. Microarray for detection and differentiation of seven swine viruses {#tbed12749-sec-0012}
------------------------------------------------------------------------

A total of 27 candidate capture probes for the seven targeted viruses and 1 non‐specific capture probe were tested on the electronic microarray with amplicons derived from the panel of 68 target viruses and 22 clinical negatives, non‐target bacteria and viruses. All amplified target virus samples reacted to their target‐specific capture probes. No cross‐reactivity with materials from healthy swine, non‐target bacteria or viruses was observed (Figure [2](#tbed12749-fig-0002){ref-type="fig"}b).

![Multiplex RT‐PCR amplicons visualized using agarose gel and QIAxcel System (a) and heat map depicting the reactivity of samples against 27 virus‐specific capture probes and one non‐specific binding probe (NSBP) (b). The panel of samples includes 58 strains of the seven targeted swine viruses, 11 oral swab samples: 267, 270, 271, 272, 273, 274, 277, 278, 279, 281, pooled 2‐day piglet, taken from healthy pigs and 11 non‐target virus and bacteria that are associated with livestock: swine influenza virus (SIV), porcine respiratory coronavirus (PRCV) KIVA, transmissible gastroenteritis virus (TGEV) TC1998, porcine circovirus 1 (PCV1), vesicular stomatitis virus (VSV) 89 GAS,*Streptococcus suis*,*Pasteurella multocida*,*Salmonella enterica* choleraesuis*, Mycoplasma hyopneumoniae*, bovine viral diarrhoea virus (BVDV) type 1 Singer, and Border disease virus (BDV) CoosBay. The viral strains tested include representatives of each of the seven FMDV serotypes, three CSFV genotypes, two ASFV genotypes and genotypes NA and EU of PRRSV. A positive signal in red represents a positive‐to‐negative ratio (P/N) of \>2, while negative results in black represent any P/N ≤ 2](TBED-65-e272-g002){#tbed12749-fig-0002}

3.3. Limits of detection {#tbed12749-sec-0013}
------------------------

Nucleic acid from 10‐fold serial dilutions of transcribed RNA of known copy number were amplified by single‐plex RT‐PCR, a duplex RT‐PCR consisting of primers for PRRSV and PCV2, a five‐plex RT‐PCR for viruses exotic to Canada (FMDV, SVDV, VESV, CSFV and ASFV) or the seven‐plex RT‐PCR. The RT‐PCR amplicons were then tested on the microarray, to determine the limit of detection of the RT‐PCRs and microarray for each virus. The assay showed similar efficiencies for the single‐plex, duplex and five‐plex RT‐PCRs and microarray for SVDV, VESV, CSFV, ASFV, PCV2 and PRRSV, but the PCR had higher sensitivity for the smaller amplicons: ASFV, PCV2 and PRRSV (Table [4](#tbed12749-tbl-0004){ref-type="table"}). The seven‐plex RT‐PCR showed the best analytical sensitivity with ASFV, PCV2 and PRRSV at a range between 1 copy in PCR and 10 copies on the electronic microarray, followed by SVDV, CSFV and VESV at around 10 and 100 copies in PCR and microarray, respectively. The detection limit was lowest for FMDV at hundreds of copies for both seven‐plex and five‐plex PCRs, and one (single‐plex, five‐plex) or two (seven‐plex) orders of magnitude lower on the microarray (Table [4](#tbed12749-tbl-0004){ref-type="table"}).

###### 

Analytical sensitivity of RT‐PCR and electronic microarray assay

  Virus                                                    Copy number   Assay detection                                 
  -------------------------------------------------------- ------------- ----------------- ---- ---- ---- ---- ---- ---- ----
  FMDV Asia 1 PAK                                          47204         \+                \+   \+        \+   \+   \+   
  4720                                                     \+            \+                \+        \+   −    \+        
  472                                                      \+            \+                \+        −    −    −         
  47                                                       S             −                 S         −    −    −         
  4                                                        −             −                 −         −    −    −         
  SVDV ITL 19/99                                           2333          \+                \+   \+        \+   \+   \+   
  233                                                      \+            \+                \+        \+   −    \+        
  23                                                       \+            S                 \+        −    −    −         
  2                                                        S             −                 S         −    −    −         
  0.2                                                      −             −                 −         −    −    −         
  CSFV Alfort/187                                          7031          \+                \+   \+        \+   \+   \+   
  703                                                      \+            \+                \+        \+   −    \+        
  70                                                       \+            −                 \+        −    −    −         
  7                                                        S             −                 S         −    −    −         
  0.7                                                      −             −                 −         −    −    −         
  VESV‐Cal                                                 1305          \+                \+   \+        \+   \+   \+   
  130                                                      \+            \+                \+        \+   −    \+        
  13                                                       \+            \+                \+        −    −    −         
  1                                                        −             −                 −         −    −    −         
  ASFV Lisbon 61[a](#tbed12749-note-0005){ref-type="fn"}   300           \+                \+   \+        \+   \+   \+   
  30                                                       \+            \+                \+        \+   \+   \+        
  3                                                        \+            \+                \+        −    −    −         
  0.3                                                      S             −                 S         −    −    −         
  0.03                                                     −             −                 −         −    −    −         
  PCV2 B[a](#tbed12749-note-0005){ref-type="fn"}           800           \+                \+        \+   \+   \+        \+
  80                                                       \+            \+                     \+   \+   \+        \+   
  8                                                        \+            \+                     \+   −    −         −    
  0.8                                                      S             −                      S    −    −         −    
  0.08                                                     −             −                      −    −    −         −    
  PRRSV LV                                                 222           \+                \+        \+   \+   \+        \+
  22                                                       \+            \+                     \+   \+   S         \+   
  2                                                        \+            \+                     \+   −    −         −    
  0.2                                                      S             −                      S    −    −         −    
  0.02                                                     −             −                      −    −    −         −    

S, suspect reactor.

Plasmid DNA.

Dilutions that gave positive signals are shaded grey.
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3.4. Testing of clinical and spiked samples {#tbed12749-sec-0014}
-------------------------------------------

Extracted nucleic acid from clinical samples was amplified using the seven‐plex multiplex assay. FMDV nucleic acid was detected in serum samples as early as 1 day post‐infection (dpi). All available targets were detected from nasal, oral, serum or whole blood with detection ranging from 1 dpi for SVDV, 4 dpi for ASFV and 5 dpi for CSFV (Table [5](#tbed12749-tbl-0005){ref-type="table"}). PRRSV was detected in positive field serum samples from swine (*n* = 10, Table [5](#tbed12749-tbl-0005){ref-type="table"}, Figure [3](#tbed12749-fig-0003){ref-type="fig"}). All samples from oral and/or nasal swab material that were spiked with VESV, PRRSV and PCV2 (*n* = 8) produced amplicons of the expected size after the multiplex PCR and the viruses were accurately detected by the microarray (data not shown).

###### 

Testing of assay with clinical and spiked biological samples

  Virus                                          Isolate                                       No. of samples   Sample type   Microarray earliest detection (dpi)   Real‐time PCR earliest detection (dpi)
  ---------------------------------------------- --------------------------------------------- ---------------- ------------- ------------------------------------- ----------------------------------------
  FMDV                                           A IRN 1/2009, O UKG 1/2011, SAT1 ZAM 9/2008   14               Serum         1                                     2
  O UKG 1/2011, SAT1 ZAM 9/2008                  10                                            Nasal            2             1                                     
  O UKG 1/2011                                   6                                             Oral             2             1                                     
  SVDV                                           PORT 1/2003, UK27/72                          36               Nasal         1                                     1
  CSFV                                           Diepholz, Honduras                            36               Serum         5                                     5
  ASFV                                           Malawi                                        24               Whole Blood   4                                     4
  VESV[a](#tbed12749-note-0007){ref-type="fn"}   Cal                                           1                Oral          Detected                              N/A
  1                                              Nasal                                         Detected         N/A                                                 
  PCV2[a](#tbed12749-note-0007){ref-type="fn"}   Weirrenga                                     1                Oral          Detected                              N/A
  1                                              Nasal                                         Detected         N/A                                                 
  PRRSV                                          2 (17‐001377‐0001_1‐57‐1)                     1                Serum         Detected                              N/A
  7 (17‐007044‐2208_1‐3‐2)                       1                                             Serum            Detected      N/A                                   
  11 (17‐010599‐0006_1‐30‐2)                     1                                             Serum            Detected      N/A                                   
  20 (17‐019861‐0006_1‐1‐1)                      1                                             Serum            Detected      N/A                                   
  21 (17‐020077‐0002_1‐8‐4)                      1                                             Serum            Detected      N/A                                   
  22 (17‐020084‐0001_1‐3‐2)                      1                                             Serum            Detected      N/A                                   
  23 (17‐020347‐0011_1‐8‐2)                      1                                             Serum            Detected      N/A                                   
  33 (17‐035‐986_1‐4‐1)                          1                                             Serum            Detected      N/A                                   
  36 (17‐039858‐0022_2‐5‐2)                      1                                             Serum            Detected      N/A                                   
  43 (17‐052259‐0023_1‐57‐1)                     1                                             Pooled           Detected      N/A                                   
  YNL (NA), LV (EU)                              2[a](#tbed12749-note-0007){ref-type="fn"}     Oral             Detected      N/A                                   
  YNL (NA), LV (EU)                              2[a](#tbed12749-note-0007){ref-type="fn"}     Nasal            Detected      N/A                                   

dpi, days post‐infection.

Biological samples spiked with virus.
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![Multiplex RT‐PCR amplicons visualized using QIAxcel System (a) and heat map depicting the reactivity of 10 genetically diverse Canadian PRRSV‐positive serum samples from diagnostic submissions against 27 virus‐specific capture probes and one non‐specific binding probe (NSBP) (b). The panel of samples includes the following: \#2 (17‐001377‐0001_1‐57‐1), \#7 (17‐007044‐2208_1‐3‐2), \#11 (17‐010599‐0006_1‐30‐2), \#20 (17‐019861‐0006_1‐1‐1), \#21 (17‐020077‐0002_1‐8‐4), \#22 (17‐020084‐0001_1‐3‐2),‐\#23 (17‐020347‐0011_1‐8‐2), \#33 (17‐035‐986_1‐4‐1), \#36 (17‐039858‐0022_2‐5‐2), \#43 (17‐052259‐0023_1‐57‐1). A positive signal in red represents a positive‐to‐negative ratio (P/N) of \>2, while negative results in black represent any P/N ≤ 2](TBED-65-e272-g003){#tbed12749-fig-0003}

In addition to samples taken prior to experimental infection at 0 dpi, nucleic acid extracted from oral swabs from 11 healthy swine did not produce any amplicons or produced weak detectable bands on agarose gels after the multiplex RT‐PCR and no reactivity above background was observed subsequently on the microarray, demonstrating 100% specificity for these samples (Figure [2](#tbed12749-fig-0002){ref-type="fig"}b).

4. DISCUSSION {#tbed12749-sec-0015}
=============

This study describes the development and initial laboratory evaluation of a novel user‐friendly microarray primarily designed for the detection and differentiation of FMDV, SVDV, VESV, CSFV, and ASFV that are exotic to North America. Due to the ability of the electronic microarray assay to print capture probes on site, RT‐PCR primers and probes for PRRSV and PCV2 were tested with available samples to evaluate the potential use of electronic microarray assays for detection of indigenous diseases. The seven‐plex RT‐PCR and electronic microarray assay successfully amplified and accurately detected laboratory amplified (*n* = 58), experimentally inoculated (spiked, *n* = 8), and PRRSV‐positive field samples (*n* = 10). All capture probes were highly specific and showed no cross‐reactivity with heterologous viruses, non‐target bacteria and viruses, or samples from healthy animals. PRRSV was originally detected in North America and Europe almost simultaneously (Christianson & Joo, [1994](#tbed12749-bib-0004){ref-type="ref"}; Lunney et al., [2016](#tbed12749-bib-0027){ref-type="ref"}). The two genotypes were genetically diverse with about 55%--70% nucleotide identity (Lunney et al., [2016](#tbed12749-bib-0027){ref-type="ref"}). Due to the high genetic diversity of RNA viruses and the lack of more PRRSV (especially genotype 2) isolates available for testing, regular evaluation of the primers and probe sequences against newly available sequences and additional validation will be needed. The large number of capture probes (up to 400 for the electronic microarray used here) should allow better coverage of genetically diverse strains compared with real‐time RT‐PCRs, which can typically accommodate only a few probes. The ability to print custom capture probes on site without additional instrumentation allows the assay to be updated conveniently.

Conventional testing methods, such as virus isolation, ELISA and PCR, have been advocated by the OIE as gold standard tests for the detection of many viral infections. Although these methods can be highly sensitive to specific viral serotypes, methods like virus isolation are time‐consuming, requiring multiple blind passages of a sample to generate usable amounts of infectious material. Additionally, multiple tests are required to detect coinfections or to differentiate between species with clinically indistinguishable signs. Although multiplex real‐time RT‐PCRs have been described for many swine pathogens (Haines et al., [2013](#tbed12749-bib-0011){ref-type="ref"}; Li et al., [2013](#tbed12749-bib-0021){ref-type="ref"}; Rasmussen et al., [2006](#tbed12749-bib-0033){ref-type="ref"}; Shi et al., [2016](#tbed12749-bib-0041){ref-type="ref"}; Wernike et al., [2012](#tbed12749-bib-0046){ref-type="ref"}, [2013](#tbed12749-bib-0045){ref-type="ref"}), the diagnosis of FMDV, SVDV, CSFV and ASFV still requires the performance of multiple single tests. Automated multiplex assays can potentially reduce labour cost and handling time. The highest analytical sensitivities observed for the 7‐plex RT‐PCR were as follows: PRRSV, PCV2 and ASFV which have the smallest amplicons (379--537 bp). Although the microarray assay successfully detected FMDV in dpi 1 samples from experimentally infected animals, the multiplex RT‐PCR was less efficient for amplification of FMDV, which had the largest amplicon size in the assay (971 bp). This is most likely due to reduced PCR efficiencies for large amplicons (Cheng, Fockler, Barnes, & Higuchi, [1994](#tbed12749-bib-0003){ref-type="ref"}; Huang, Arnheim, & Goodman, [1992](#tbed12749-bib-0015){ref-type="ref"}). The FMDV primers used in this study were specifically designed to amplify the highly variable VP1 capsid protein coding region to allow subtyping into the seven known FMDV serotypes either in the same assay or in a separate assay (unpublished results) or by sequencing. The choice of RT‐PCR primers that generates a smaller FMDV amplicon could (e.g., Moniwa et al., [2007](#tbed12749-bib-0029){ref-type="ref"}) potentially further increase the detection limit of the assay for FMDV. With 22 primers in the described multiplex RT‐PCR, there may also be interactions between the different primers that reduce the efficiency of the amplification. When the PCR primers for PRRSV and PCV2 were removed and placed in a separate RT‐PCR, an increase in sensitivity was observed for FMDV, SVDV, VESV and CSFV. The electronic microarray component of the assay showed a reduction in sensitivity for some target pathogens both in this and other studies (Lung et al., [2016](#tbed12749-bib-0024){ref-type="ref"}, [2017](#tbed12749-bib-0025){ref-type="ref"} and unpublished results) when compared with the RT‐PCR component of the assay. Possible explanations for this reduction in sensitivity at the microarray stage could be the formation of secondary structure of certain capture probes, the amplicon or the annealing of the two strands of the amplicons which could prevent efficient hybridization between the capture probes and the amplicon under the experimental conditions. The use of asymmetric PCR to generate single‐stranded products, increased amount of capture probe and/or amplicon may also further increase the sensitivity of the assay. Although not tested in this study due to resource constraints, previously published electronic microarray assays for detection of avian, swine and bovine viruses (Lung et al., [2012](#tbed12749-bib-0022){ref-type="ref"}, [2016](#tbed12749-bib-0024){ref-type="ref"}, [2017](#tbed12749-bib-0025){ref-type="ref"}), were able to detect the presence of more than one target. Due to potentially high loads of viruses such as PCV2 in many countries, the splitting of the seven‐plex RT‐PCR into a duplex RT‐PCR for PRRSV and PCV2 and a five‐plex RT‐PCR for the other viruses, as described in this study, will improve the sensitivity of the assay for the detection of reportable diseases.

Although an RT step was not required for DNA viruses, previous studies have shown better amplification of the DNA targets when a RT step was included (Lung et al., [2017](#tbed12749-bib-0025){ref-type="ref"}). This could be due to the utilization of messenger RNAs as well as genomic DNA as template (Lung et al., [2017](#tbed12749-bib-0025){ref-type="ref"}). Further improvements in assay sensitivity and integration of the PCR with the electronic microarray in the new NanoChip400 XL electronic microarray platform could make this novel automated microarray technology a useful tool for multipathogen detection and subtyping.
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